Research ExplorerScientific StaffKatja Weisel Publications

Prof.Dr.med. ID: 6488383

Katja Weisel

graph of relations
Affiliations
151 - 200 out of 245Page size: 50
Sort by: Type

Publications

  1. SCORING: Journal article › Research › Peer-reviewed

  2. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

    Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., Dimopoulos, M., Stewart, A. K., Richter, J., Vij, R., Tuchman, S., Raab, M. S., Weisel, K. C., Delforge, M., Cornell, R. F., Kaminetzky, D., Hoffman, J. E., Costa, L. J., Parker, T. L., Levy, M., Schreder, M., Meuleman, N., Frenzel, L., Mohty, M., Choquet, S., Schiller, G., Comenzo, R. L., Engelhardt, M., Illmer, T., Vlummens, P., Doyen, C., Facon, T., Karlin, L., Perrot, A., Podar, K., Kauffman, M. G., Shacham, S., Li, L., Tang, S., Picklesimer, C., Saint-Martin, J-R., Crochiere, M., Chang, H., Parekh, S., Landesman, Y., Shah, J., Richardson, P. G. & Jagannath, S., 22.08.2019, In: NEW ENGL J MED. 381, 8, p. 727-738 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. Osteoprotegerin positively regulates hematopoietic progenitor cells

    Schweikle, E., Baessler, T., Yildirim, S., Kanz, L., Möhle, R. & Weisel, K. C., 01.2012, In: CURR STEM CELL RES T. 7, 1, p. 72-7 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  4. Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation

    Thiele, B., Binder, M., Schliffke, S., Frenzel, C., Dierlamm, J., Wass, M., Weisel, K. C., Bokemeyer, C. & Janjetovic, S., 21.07.2021, In: ONCOL RES TREAT. 44, 7-8, p. 375-381 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

    Avivi, I., Vesole, D. H., Davila-Valls, J., Usnarska-Zubkiewicz, L., Olszewska-Szopa, M., Milunovic, V., Baumert, B., Osękowska, B., Kopińska, A., Gentile, M., Puertas-Martinez, B., Robak, P., Crusoe, E., Rodriguez-Lobato, L. G., Gajewska, M., Varga, G., Delforge, M., Cohen, Y., Gozzetti, A., Pena, C., Shustik, C., Mikala, G., Zalac, K., Alexander, H. D., Barth, P., Weisel, K., Martínez-López, J., Waszczuk-Gajda, A., Krzystański, M. & Jurczyszyn, A., 01.09.2023, In: CANCERS. 15, 17, 4359.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  6. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

    Morgan, G., Palumbo, A., Dhanasiri, S., Lee, D., Weisel, K., Facon, T., Delforge, M., Oriol, A., Zaki, M., Yu, X., Sternas, L., Jacques, C., Akehurst, R., Offner, F. & Dimopoulos, M. A., 03.2015, In: BRIT J HAEMATOL. 168, 6, p. 820-3 4 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Sonneveld, P., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M-V., Mark, T. M., Levin, M-D., Ahmadi, T., Qin, X., Garvin Mayo, W., Gai, X., Carey, J., Carson, R. & Spencer, A., 10.03.2023, In: J CLIN ONCOL. 41, 8, p. 1600-1609 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  8. Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report

    Dorn, C., Bugl, S., Malenke, E., Müller, M. R., Weisel, K. C., Vogel, U., Horger, M., Kanz, L. & Kopp, H-G., 23.05.2014, In: BMC RES NOTES. 7, p. 313

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  9. Pathologic fractures in patients with multiple myeloma undergoing bisphosphonate therapy: incidence and correlation with course of disease

    Vogel, M. N., Weisel, K., Maksimovic, O., Peters, S., Brodoefel, H., Claussen, C. D. & Horger, M. S., 09.2009, In: AM J ROENTGENOL. 193, 3, p. 656-61 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  10. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

    Merz, M., Salwender, H., Haenel, M., Mai, E. K., Bertsch, U., Kunz, C., Hielscher, T., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Hillengass, J., Raab, M. S., Schurich, B., Munder, M., Brossart, P., Gerecke, C., Lindemann, H-W., Zeis, M., Weisel, K., Duerig, J. & Goldschmidt, H., 12.2016, In: HAEMATOLOGICA. 101, 12, p. e485-e487

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  11. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Davies, F. E., Pawlyn, C., Usmani, S. Z., San-Miguel, J. F., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., Sonneveld, P., Stewart, A. K., Bergsagel, P. L., Kaiser, M. F., Weisel, K., Keats, J. J., Mikhael, J. R., Morgan, K. E., Ghobrial, I. M., Orlowski, R. Z., Landgren, C. O., Gay, F., Caers, J., Chng, W. J., Chari, A., Walker, B. A., Kumar, S. K., Costa, L. J., Anderson, K. C. & Morgan, G. J., 06.07.2022, In: BLOOD CANCER DISCOV. 3, 4, p. 273-284 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

    Mai, E. K., Bertsch, U., Dürig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W., Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H. & Goldschmidt, H., 08.2015, In: LEUKEMIA. 29, 8, p. 1721-9 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  13. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

    Weisel, K., Dimopoulos, M., Song, K. W., Moreau, P., Palumbo, A., Belch, A., Schey, S., Sonneveld, P., Sternas, L., Yu, X., Amatya, R., Gibson, C. J., Zaki, M., Jacques, C. & San Miguel, J., 09.2015, In: CL LYMPH MYELOM LEUK. 15, 9, p. 519-30 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  14. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics

    Richardson, P. G., Schjesvold, F., Weisel, K., Moreau, P., Anderson, L. D., White, D., Rodriguez-Otero, P., Sonneveld, P., Engelhardt, M., Jenner, M., Corso, A., Dürig, J., Pavic, M., Salomo, M., Beksac, M., Oriol, A., Lindsay, J., Liberati, A. M., Galli, M., Robak, P., Larocca, A., Yagci, M., Vural, F., Kanate, A. S., Jiang, R., Grote, L., Peluso, T. & Dimopoulos, M., 01.2022, In: EUR J HAEMATOL. 108, 1, p. 73-83 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  15. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    Dimopoulos, M., Weisel, K., Moreau, P., Anderson, L. D., White, D., San-Miguel, J., Sonneveld, P., Engelhardt, M., Jenner, M., Corso, A., Dürig, J., Pavic, M., Salomo, M., Casal, E., Srinivasan, S., Yu, X., Nguyen, T. V., Biyukov, T., Peluso, T. & Richardson, P., 06.2021, In: LEUKEMIA. 35, 6, p. 1722-1731 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  16. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., San Miguel, J., Sunami, K., O'Gorman, P., Sonneveld, P., Robak, P., Semochkin, S., Schey, S., Yu, X., Doerr, T., Bensmaine, A., Biyukov, T., Peluso, T., Zaki, M., Anderson, K., Dimopoulos, M. & OPTIMISMM trial investigators, 06.2019, In: LANCET ONCOL. 20, 6, p. 781-794 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  17. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

    Siegel, D. S., Weisel, K. C., Dimopoulos, M. A., Baz, R., Richardson, P., Delforge, M., Song, K. W., San Miguel, J. F., Moreau, P., Goldschmidt, H., Cavo, M., Jagannath, S., Yu, X., Hong, K., Sternas, L., Zaki, M. & Palumbo, A., 12.2016, In: LEUKEMIA LYMPHOMA. 57, 12, p. 2833-2838 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  18. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

    Dimopoulos, M., Weisel, K., van de Donk, N. W. C. J., Ramasamy, K., Gamberi, B., Streetly, M., Offidani, M., Bridoux, F., de la Rubia, J., Mateos, M-V., Ardizzoia, A., Kueenburg, E., Collins, S., Di Micco, A., Rosettani, B., Li, Y., Bacon, P. & Sonneveld, P., 10.07.2018, In: J CLIN ONCOL. 36, 20, p. 2035-2043 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  19. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Miguel, J. S., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., Alegre, A., Chen, C., Cavo, M., Garderet, L., Ivanova, V., Martinez-Lopez, J., Belch, A., Palumbo, A., Schey, S., Sonneveld, P., Yu, X., Sternas, L., Jacques, C., Zaki, M. & Dimopoulos, M., 10.2013, In: LANCET ONCOL. 14, 11, p. 1055-1066 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  20. Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

    Li, Y., Wang, X., O'Mara, E., Dimopoulos, M. A., Sonneveld, P., Weisel, K. C., Matous, J., Siegel, D. S., Shah, J. J., Kueenburg, E., Sternas, L., Cavanaugh, C., Zaki, M., Palmisano, M. & Zhou, S., 2017, In: CLIN PHARMACOL-ADV A. 9, p. 133-145 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  21. Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment

    Ghandili, S., Schönlein, M., Lütgehetmann, M., Wiesch, J. S. Z., Becher, H., Bokemeyer, C., Sinn, M., Weisel, K. C. & Leypoldt, L. B., 28.07.2021, In: CANCERS. 13, 15, 3800.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  22. Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis

    Manier, S., Dimopoulos, M., Hulin, C., Leleu, X., Delforge, M., Weisel, K., Mouro, J., Costa, B., Sturniolo, M. & Facon, T., 09.2023, In: CL LYMPH MYELOM LEUK. 23, 9, p. e297-e306.e1

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  23. Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

    Klein, E-M., Tichy, D., Salwender, H. J., Mai, E. K., Duerig, J., Weisel, K. C., Benner, A., Bertsch, U., Akhavanpoor, M., Besemer, B., Munder, M., Lindemann, H-W., Hose, D., Seckinger, A., Luntz, S., Jauch, A., Elmaagacli, A., Fuhrmann, S., Brossart, P., Goerner, M., Bernhard, H., Raab, M. S., Blau, I. W., Haenel, M., Scheid, C., Goldschmidt, H. & On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg, 28.09.2021, In: CANCERS. 13, 19, p. 4856

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  24. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

    Merz, M., Jauch, A., Hielscher, T., Bochtler, T., Schönland, S. O., Seckinger, A., Hose, D., Bertsch, U., Neben, K., Raab, M. S., Hillengass, J., Salwender, H., Blau, I. W., Lindemann, H-W., Schmidt-Wolf, I. G. H., Scheid, C., Haenel, M., Weisel, K. C. & Goldschmidt, H., 09.01.2018, In: BLOOD ADV. 2, 1, p. 1-9 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  25. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA

    Cavo, M., San-Miguel, J. F. F., Usmani, S. Z., Weisel, K. C., Dimopoulos, M. A. A., Avet-Loiseau, H., Paiva, B., Bahlis, N. J., Plesner, T., Hungria, V. T. D. M., Moreau, P., Mateos, M. V., Perrot, A., Iida, S., Facon, T., Kumar, S. K., van de Donk, N. W. C. J., Sonneveld, P., Spencer, A., Krevvata, M., Heuck, C., Wang, J., Ukropec, J., Kobos, R., Sun, S., Qi, M. & Munshi, N. C., 10.02.2022, In: BLOOD. 139, 6, p. 835-844 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  26. Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma

    Hartmann, J. T., Meisinger, I., Kröber, S. M., Weisel, K., Klingel, K. & Kanz, L., 12.2006, In: HAEMATOLOGICA. 91, 12 Suppl, p. ECR49

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  27. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

    Hose, D., Beck, S., Salwender, H., Emde, M., Bertsch, U., Kunz, C., Scheid, C., Hänel, M., Weisel, K., Hielscher, T., Raab, M. S., Goldschmidt, H., Jauch, A., Moreaux, J. & Seckinger, A., 26.06.2019, In: J HEMATOL ONCOL. 12, 1, p. 65

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  28. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation

    Guthoff, M., Schmid-Horch, B., Weisel, K. C., Häring, H-U., Königsrainer, A. & Heyne, N., 06.2012, In: TRANSPL IMMUNOL. 26, 4, p. 171-5 5 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  29. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

    Ludwig, H., Pönisch, W., Knop, S., Egle, A., Hinke, A., Schreder, M., Lechner, D., Hajek, R., Gunsilius, E., Petzer, A., Weisel, K., Niederwieser, D., Einsele, H., Willenbacher, W., Rumpold, H., Pour, L., Jelinek, T., Krenosz, K. J., Meckl, A., Nolte, S., Melchardt, T., Greil, R. & Zojer, N., 02.2020, In: LEUKEMIA LYMPHOMA. 61, 2, p. 377-386 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  30. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

    Thompson, M. A., Boccadoro, M., Leleu, X., Vela-Ojeda, J., van Rhee, F., Weisel, K. C., Rifkin, R. M., Usmani, S. Z., Hájek, R., Cook, G., Abonour, R., Armour, M., Morgan, K. E., Yeh, S-P., Costello, C. L., Berdeja, J. G., Davies, F. E., Zonder, J. A., Lee, H. C., Omel, J., Spencer, A., Terpos, E., Hungria, V. T. M., Puig, N., Fu, C., Ferrari, R. H., Ren, K., Stull, D. M. & Chari, A., 03.2023, In: CL LYMPH MYELOM LEUK. 23, 3, p. e171-e181

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  31. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

    Salwender, H., Bertsch, U., Weisel, K., Duerig, J., Kunz, C., Benner, A., Blau, I. W., Raab, M. S., Hillengass, J., Hose, D., Huhn, S., Hundemer, M., Andrulis, M., Jauch, A., Seidel-Glaetzer, A., Lindemann, H-W., Hensel, M., Fronhoffs, S., Martens, U., Hansen, T., Wattad, M., Graeven, U., Munder, M., Fenk, R., Haenel, M., Scheid, C. & Goldschmidt, H., 28.05.2019, In: BMC CANCER. 19, 1, p. 504

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  32. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

    Baertsch, M-A., Schlenzka, J., Mai, E. K., Merz, M., Hillengaß, J., Raab, M. S., Hose, D., Wuchter, P., Ho, A. D., Jauch, A., Hielscher, T., Kunz, C., Luntz, S., Klein, S., Schmidt-Wolf, I. G. H., Goerner, M., Schmidt-Hieber, M., Reimer, P., Graeven, U., Fenk, R., Salwender, H., Scheid, C., Nogai, A., Haenel, M., Lindemann, H. W., Martin, H., Noppeney, R., Weisel, K. & Goldschmidt, H., 25.04.2016, In: BMC CANCER. 16, p. 290

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  33. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

    Davies, F., Rifkin, R., Costello, C., Morgan, G., Usmani, S., Abonour, R., Palumbo, A., Romanus, D., Hajek, R., Terpos, E., Cherepanov, D., Stull, D. M., Huang, H., Leleu, X., Berdeja, J., Lee, H. C., Weisel, K., Thompson, M., Boccadoro, M., Zonder, J., Cook, G., Puig, N., Vela-Ojeda, J., Farrelly, E., Raju, A., Blazer, M. & Chari, A., 09.2021, In: ANN HEMATOL. 100, 9, p. 2325-2337 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  34. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy

    Weisel, K., Wadlund, A. O., Gungor, G., Dergarabetian, E., Pacheco, C., Masurkar, N. & Rodriguez-Otero, P., 10.2022, In: EUR J HAEMATOL. 109, 4, p. 388-397 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  35. Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells

    Weisel, K. C., Yildirim, S., Schweikle, E., Kanz, L. & Möhle, R., 03.2009, In: ANN HEMATOL. 88, 3, p. 203-11 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  36. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)

    Moreau, P., Weisel, K. C., Song, K. W., Gibson, C. J., Saunders, O., Sternas, L. A., Hong, K., Zaki, M. H. & Dimopoulos, M. A., 12.2016, In: LEUKEMIA LYMPHOMA. 57, 12, p. 2839-2847 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  37. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis

    Ramasamy, K., Dhanasiri, S., Thom, H., Buchanan, V., Robinson, S., D'Souza, V. K. & Weisel, K., 03.2020, In: LEUKEMIA LYMPHOMA. 61, 3, p. 668-679 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  38. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

    Goldschmidt, H., Mai, E. K., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Bertsch, U., Hielscher, T., Merz, M., Munder, M., Lindemann, H-W., Hügle-Dörr, B., Tichy, D., Giesen, N., Hose, D., Seckinger, A., Huhn, S., Luntz, S., Jauch, A., Elmaagacli, A., Rabold, B., Fuhrmann, S., Brossart, P., Goerner, M., Bernhard, H., Hoffmann, M., Hillengass, J., Raab, M. S., Blau, I. W., Hänel, M., Salwender, H. J. & German-speaking Myeloma Multicenter Group (GMMG), 07.2020, In: LEUKEMIA. 34, 7, p. 1853-1865 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  39. Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging: a feasibility study

    Fenchel, M., Konaktchieva, M., Weisel, K., Kraus, S., Claussen, C. D. & Horger, M., 11.2010, In: ACAD RADIOL. 17, 11, p. 1326-33 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  40. Rhabdomyolysis and acute kidney injury

    Heyne, N., Guthoff, M. & Weisel, K. C., 01.10.2009, In: NEW ENGL J MED. 361, 14, p. 1412; author reply 1412-3

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  41. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

    Emde-Rajaratnam, M., Beck, S., Benes, V., Salwender, H., Bertsch, U., Scheid, C., Hänel, M., Weisel, K., Hielscher, T., Raab, M. S., Goldschmidt, H., Jauch, A., Maes, K., De Bruyne, E., Menu, E., De Veirman, K., Moreaux, J., Vanderkerken, K., Seckinger, A. & Hose, D., 2023, In: FRONT IMMUNOL. 14, p. 1286700

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  42. Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data

    Pintoffl, J. P., Weisel, K., Schulze, M., Maksimovic, O., Claussen, C. D., Kramer, U. & Horger, M., 10.2013, In: J ULTRAS MED. 32, 10, p. 1777-88 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  43. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

    Dimopoulos, M. A., Palumbo, A., Corradini, P., Cavo, M., Delforge, M., Di Raimondo, F., Weisel, K. C., Oriol, A., Hansson, M., Vacca, A., Blanchard, M. J., Goldschmidt, H., Doyen, C., Kaiser, M., Petrini, M., Anttila, P., Cafro, A. M., Raymakers, R., San-Miguel, J., de Arriba, F., Knop, S., Röllig, C., Ocio, E. M., Morgan, G., Miller, N., Simcock, M., Peluso, T., Herring, J., Sternas, L., Zaki, M. H. & Moreau, P., 28.07.2016, In: BLOOD. 128, 4, p. 497-503 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  44. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

    Goldschmidt, H., Baertsch, M-A., Schlenzka, J., Becker, N., Habermehl, C., Hielscher, T., Raab, M-S., Hillengass, J., Sauer, S., Müller-Tidow, C., Luntz, S., Jauch, A., Hose, D., Seckinger, A., Brossart, P., Goerner, M., Klein, S., Schmidt-Hieber, M., Reimer, P., Graeven, U., Fenk, R., Haenel, M., Martin, H., Lindemann, H. W., Scheid, C., Nogai, A., Salwender, H., Noppeney, R., Besemer, B., Weisel, K. & German Myeloma Multicenter Group (GMMG), 04.2021, In: LEUKEMIA. 35, 4, p. 1134-1144 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  45. Selective elimination of immunosuppressive T cells in patients with multiple myeloma

    Awwad, M. H. S., Mahmoud, A., Bruns, H., Echchannaoui, H., Kriegsmann, K., Lutz, R., Raab, M. S., Bertsch, U., Munder, M., Jauch, A., Weisel, K., Maier, B., Weinhold, N., Salwender, H. J., Eckstein, V., Hänel, M., Fenk, R., Dürig, J., Brors, B., Benner, A., Müller-Tidow, C., Goldschmidt, H. & Hundemer, M., 09.2021, In: LEUKEMIA. 35, 9, p. 2602-2615 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  46. Severe psychotic disorder and agranulocytosis--a therapeutic dilemma

    Borbé, R., Weisel, K., Sachs, U. J. H. & Steinert, T., 11.2009, In: PHARMACOPSYCHIATRY. 42, 6, p. 284-5 2 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  47. Stromal cell lines from the aorta-gonado-mesonephros region are potent supporters of murine and human hematopoiesis

    Weisel, K. C., Gao, Y., Shieh, J-H. & Moore, M. A. S., 11.2006, In: Experimental hematology. 34, 11, p. 1505-16 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  48. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

    Merz, M., Salwender, H., Haenel, M., Mai, E. K., Bertsch, U., Kunz, C., Hielscher, T., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Hillengass, J., Raab, M. S., Schurich, B., Munder, M., Schmidt-Wolf, I. G. H., Gerecke, C., Lindemann, H-W., Zeis, M., Weisel, K., Duerig, J. & Goldschmidt, H., 07.2015, In: HAEMATOLOGICA. 100, 7, p. 964-9 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  49. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

    Landgren, O., Weisel, K., Rosinol, L., Touzeau, C., Turgut, M., Hajek, R., Mollee, P., Kim, J. S., Shu, N., Hu, X., Li, C. & Usmani, S. Z., 09.2022, In: BRIT J HAEMATOL. 198, 6, p. 988-993 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  50. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers

    Oehrlein, K., Langer, C., Sturm, I., Pönisch, W., Hahn-Ast, C., Kuhn, S. & Weisel, K. C., 06.2012, In: CL LYMPH MYELOM LEUK. 12, 3, p. 191-6 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  51. Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion

    Weinstock, C., Möhle, R., Dorn, C., Weisel, K., Höchsmann, B., Schrezenmeier, H. & Kanz, L., 03.2015, In: TRANSFUSION. 55, 3, p. 605-10 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Previous 1 2 3 4 5 Next